Common side effects observed in monotherapy trials, similar to other GLP-1 receptor agonists, include gastrointestinal symptoms such as nausea, diarrhea, and vomiting, with most adverse events being mild to moderate in severity
Escalate When It Persists Recurring symptoms despite focused changes need medical evaluation rather than a longer and more restrictive elimination list
Apply a cold compress for the first 10 minutes after injection if needed
Some individuals lose more, particularly those with higher starting weights or those who are especially responsive to the appetite-suppressing effects
The initial phase focuses on helping you tolerate the dose while Semaglutide GLP-1 starts influencing appetite regulation and digestion
Study Selection The trials we included met the following criteria: (1) RCTs that compared GLP-1 receptor agonist with a placebo or active control (other antidiabetic drugs or insulin), (2) patients with type 2 diabetes, type 1 diabetes, prediabetes, overweight or obesity, (3) with durations of at least 24 weeks, and (4) reported the occurrence of at least one case of various thyroid disorders as adverse events
